Cargando…

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series

Fulvestrant is a pure estrogen receptor (ER) antagonist approved for the treatment of metastatic ER positive breast cancer in postmenopausal women with disease progression following antiestrogen therapy. The clinical results of fulvestrant demonstrated encouraging activity in tumors in spite of HER2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rusz, Orsolya, Kószó, Renáta, Dobi, Ágnes, Csenki, Melinda, Valicsek, Erzsébet, Nikolényi, Alíz, Uhercsák, Gabriella, Cserháti, Adrienne, Kahán, Zsuzsanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129034/ https://www.ncbi.nlm.nih.gov/pubmed/30233207 http://dx.doi.org/10.2147/OTT.S170736

Ejemplares similares

BC-Monitor: Towards a Routinely Accessible Circulating Tumor DNA-Based Tool for Real-Time Monitoring Breast Cancer Progression and Treatment Effectiveness
por: Priskin, Katalin, et al.
Publicado: (2021)

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
por: Maráz, Anikó, et al.
Publicado: (2018)

Radiation dose to the nodal regions during prone versus supine breast irradiation
por: Csenki, Melinda, et al.
Publicado: (2014)

Predictive Potential of RNA Polymerase B (II) Subunit 1 (RPB1) Cytoplasmic Aggregation for Neoadjuvant Chemotherapy Failure
por: Nagy-Mikó, Bence, et al.
Publicado: (2023)

BC-miR: Monitoring Breast Cancer-Related miRNA Profile in Blood Sera—A Prosperous Approach for Tumor Detection
por: Borsos, Barbara N., et al.
Publicado: (2022)

Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy
por: Sejben, Anita, et al.
Publicado: (2020)

Individually selected teletherapy technique for accelerated partial breast irradiation
por: Kószó, Renáta L., et al.
Publicado: (2021)

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(−) breast cancer that had progressed during or after prior endocrine therapy
por: Musolino, Antonino, et al.
Publicado: (2017)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer
por: Liu, Qi, et al.
Publicado: (2023)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Predictors of fulvestrant long-term benefit in hormone receptor-positive/HER2 negative advanced breast cancer
por: Torrisi, Rosalba, et al.
Publicado: (2022)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Efficacy and Safety of Giant Condyloma Acuminatum with Monotherapy of Topical Traditional Chinese Medicine: Report of Eight Cases
por: Wang, Mei-fang, et al.
Publicado: (2021)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
por: Bocchia, Monica, et al.
Publicado: (2022)

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)
por: Watanabe, Kenichi, et al.
Publicado: (2023)

Multimodal images of chronic branch retinal vein occlusion
por: Schwartz, Stephen G, et al.
Publicado: (2017)

Central Serous Chorioretinopathy: Multimodal Imaging and Management Options
por: Iyer, Prashanth G., et al.
Publicado: (2020)

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
por: Ngoi, N.Y.L., et al.
Publicado: (2018)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Qualifying the T-2 Toxin-Degrading Properties of Seven Microbes with Zebrafish Embryo Microinjection Method
por: Garai, Edina, et al.
Publicado: (2020)

Evaluation of the Multimycotoxin-Degrading Efficiency of Rhodococcus erythropolis NI1 Strain with the Three-Step Zebrafish Microinjection Method
por: Garai, Edina, et al.
Publicado: (2021)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Deep-inspirational breath-hold (DIBH) technique in left-sided breast cancer: various aspects of clinical utility
por: Gaál, Szilvia, et al.
Publicado: (2021)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

Low Fraction Size Re-irradiation for Large Volume Recurrence of Glial Tumours
por: Dobi, Ágnes, et al.
Publicado: (2020)

Optical coherence tomography angiography and multimodal imaging in the management of coats’ disease
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort
por: Pipek, Orsolya, et al.
Publicado: (2023)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Multimodal Imaging Characteristics and Presumed Cause of Intrapapillary Hemorrhage with Adjacent Peripapillary Subretinal Hemorrhage
por: Zhang, Xian, et al.
Publicado: (2021)

A customized multimodality approach for prolonged air leaks (PAL) in mechanically ventilated patients
por: Bansal, Sameer, et al.
Publicado: (2023)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lq7gsbrghto3glib36usspdokv